Citation Impact
Citing Papers
Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial
2011
Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer
2014
ATP-Citrate Lyase Links Cellular Metabolism to Histone Acetylation
2009 StandoutScience
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
2005 StandoutScience
High burden and pervasive positive selection of somatic mutations in normal human skin
2015 StandoutScience
Regulation of the Different Chromatin States of Autosomes and X Chromosomes in the Germ Line of C. elegans
2002 Science
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
2008 Standout
TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth
2007
Targeted therapies: a new generation of cancer treatments.
2008
Hallmarks of Cancer: The Next Generation
2011 Standout
Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
2008
Oncogenic KRAS signalling in pancreatic cancer
2014
The Pathology and Genetics of Metastatic Pancreatic Cancer
2009
Smarter drugs emerging in pancreatic cancer therapy
2014
EGFR Antagonists in Cancer Treatment
2008 Standout
Comparative Effectiveness and Health Care Spending — Implications for Reform
2010
EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma
2012
S-1 in the treatment of pancreatic cancer
2014
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Pancreatic cancer genomics
2014
Pancreatic cancer
2004 Standout
Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma
2010
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
2008 Standout
Retinoic acid receptors: From molecular mechanisms to cancer therapy
2014
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
2013 Standout
Understanding the language of Lys36 methylation at histone H3
2012
Influence of Metabolism on Epigenetics and Disease
2013 StandoutNobel
Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
2012 Standout
Genetically engineered mouse models of pancreatic adenocarcinoma
2013
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Epigenetic regulation of normal and malignant hematopoiesis
2007
Mechanisms of chromosomal translocations in B cell lymphomas
2001
Lung Cancer
2008 Standout
Epidermal Growth Factor Receptor Targeting in Cancer
2006
Advanced pancreatic carcinoma: current treatment and future challenges
2010
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
2010 StandoutNature
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Pancreatic cancer
2016 Standout
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
AID Is Required for c-myc/IgH Chromosome Translocations In Vivo
2004 StandoutNobel
Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes
2008
MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites
2011 Nature
AID is required for germinal center–derived lymphomagenesis
2007 StandoutNobel
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
2010 Standout
Multiple myeloma–associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stress
2012
Pancreatic Adenocarcinoma
2014 Standout
Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer
2017 StandoutNobel
Somatic misexpression of germline P granules and enhanced RNA interference in retinoblastoma pathway mutants
2005 StandoutNatureNobel
Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy
2006
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
Requirement of Non-canonical Activity of Uracil DNA Glycosylase for Class Switch Recombination
2006 StandoutNobel
Cardiovascular Complications of Cancer Therapy
2009
Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours
2001
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
2010
NSD3, a New SET Domain-Containing Gene, Maps to 8p12 and Is Amplified in Human Breast Cancer Cell Lines
2001
Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
2006
Characterization of soluble and exosomal forms of the EGFR released from pancreatic cancer cells
2011
Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies
2018
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
2017 StandoutNature
Pancreatic Cancer
2010 Standout
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
2010
Strategies for optimizing combinations of molecularly targeted anticancer agents
2006
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
2015 StandoutNature
Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer
2007
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
Clinical pharmacokinetics of tyrosine kinase inhibitors
2009
The occurrence and significance of V gene mutations in B cell—Derived human malignancy
2001
The molecular basis of ATM-dependent dimerization of the Mdc1 DNA damage checkpoint mediator
2012 StandoutNobel
COVID-Net: a tailored deep convolutional neural network design for detection of COVID-19 cases from chest X-ray images
2020 Standout
Genetics and biology of pancreatic ductal adenocarcinoma
2006
Fluorouracil-based Chemoradiation with Either Gemcitabine or Fluorouracil Chemotherapy after Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the U.S. Intergroup/RTOG 9704 Phase III Trial
2011
Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second‐line therapy for patients with advanced pancreatic cancer
2008
Pancreatic cancer
2011 Standout
A trithorax-group complex purified from Saccharomyces cerevisiae is required for methylation of histone H3
2001 StandoutNobel
Structure of the STRA6 receptor for retinol uptake
2016 StandoutScienceNobel
Activation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice
2007 StandoutNobel
Bidirectional Photomodulation of Surface Tension in Langmuir Films
2016 StandoutNobel
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
A Perspective on Cancer Cell Metastasis
2011 StandoutScience
Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment
2009
Metastatic Pancreatic Cancer 2008: Is the Glass Less Empty?
2008
Use of a Lipid-Coated Mesoporous Silica Nanoparticle Platform for Synergistic Gemcitabine and Paclitaxel Delivery to Human Pancreatic Cancer in Mice
2015
Capecitabine Plus Erlotinib in Gemcitabine-Refractory Advanced Pancreatic Cancer
2007
The Pancreas Cancer Microenvironment
2012
Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer
2007
Randomized phase II /III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS ‐PC Study
2015
Metabolic reprogramming and cancer progression
2020 StandoutScience
Genetics and Cytogenetics of Multiple Myeloma
2004
A systematic dissection of determinants and consequences of snoRNA-guided pseudouridylation of human mRNA
2022 StandoutNobel
Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression
2012 StandoutNobel
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Illegitimate switch recombinations are present in approximately half of primary myeloma tumors, but do not relate to known prognostic indicators or survival
2001
Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer
2006
Clinical Benefit and Quality of Life in Patients With Advanced Pancreatic Cancer Receiving Gemcitabine Plus Capecitabine Versus Gemcitabine Alone: A Randomized Multicenter Phase III Clinical Trial—SAKK 44/00–CECOG/PAN.1.3.001
2008
DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer
2009
Emerging Targets in Photopharmacology
2016 StandoutNobel
The pathology and genetics of metastatic pancreatic cancer.
2009
Genetics and biology of pancreatic ductal adenocarcinoma
2016
Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies
2007
Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
2011
Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial
2007
Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
2009
Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition
2007
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
2009 StandoutScience
Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)
2010
Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
2009
Works of Robert Lim being referenced
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007 Standout
A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group
2010
Canadian Society of Thoracic Radiology/Canadian Association of Radiologists Consensus Statement Regarding Chest Imaging in Suspected and Confirmed COVID-19
2020
The t(4;14) Translocation in Myeloma Dysregulates Both FGFR3and a Novel Gene, MMSET, Resulting in IgH/MMSET Hybrid Transcripts
1998
The t(4;14) Translocation in Myeloma Dysregulates Both FGFR3and a Novel Gene, MMSET, Resulting in IgH/MMSET Hybrid Transcripts
1998
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2023